Limited-stage Small-cell Lung Cancer
Conditions
Interventions
None listed
Sponsors
Chiba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consecutive cases that meet all of the following: 1) Patients diagnosed with limited-stage small-cell lung cancer 2) Patients who started chemoradiotherapy with curative intent at a standard radiation dose (45 Gy or more for accelerated hyperfractionation, 60 Gy or more for conventional irradiation) between 2015 and 2021 (including once-daily irradiation and sequential chemoradiotherapy Note: If radiotherapy is initiated for curative intent, patients are considered eligible even if radiotherapy is suspended or terminated during the course of treatment due to adverse events or other reasons. Therefore, in cases where a lower dose than the standard dose was administered, the reason should be confirmed, and eligibility should be determined. 3) Patients that received cisplatin/etoposide or carboplatin/etoposide as combination chemotherapy
Exclusion criteria
Exclusion criteria: Cases meeting any of the following criteria will be excluded from the study: 1) Patients receiving chemoradiotherapy as adjuvant treatment after surgery 2) Patients who choose to opt-out
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of symptomatic pneumonitis (= Grade 2 or higher) as the primary event and the risk factors involved in its development in patients who received accelerated hyperfractionated irradiation | — |
Countries
Japan
Contacts
Public ContactGo Saito
Chiba University Hospital Department of Respiratory Medicine
Outcome results
None listed